Meeting
2023 ASCO Annual Meeting
Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).
Authors
Salvatore Siena
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, University of Milano, Milan, Italy
Salvatore Siena , Alessio Amatu , Katia Bencardino , M. Giulia Zampino , Francesca Bergamo , Stefania Mosconi , Francesco Bracco , Marianna Alessandra Gerardi , Sara Galuppo , Pietro Carnevali , Wanda Petz , Pierluigi Pilati , Federica Tosi , Sara Mariano , Erica Bonazzina , Edoardo Forti , Silvia Ghezzi , Salvatore Pucciarelli , Valter Torri , Andrea Sartore-Bianchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Clinical Trial Registration Number
2017-003671-60
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3633)
DOI
10.1200/JCO.2023.41.16_suppl.TPS3633
Abstract #
TPS3633
Poster Bd #
328b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2023 ASCO Annual Meeting
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.
First Author: Jesse Joshua Smith
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer.
First Author: Jun Watanabe
Poster
2022 ASCO Annual Meeting
Total neoadjuvant chemoradiation combined with neoadjuvant PD-1 blockade for patients with pMMR, high-risk, and locally advanced middle to low rectal cancer.
First Author: Aiwen WU